Literature DB >> 28089571

Normo- and hyperandrogenic women with polycystic ovary syndrome exhibit an adverse metabolic profile through life.

Pekka Pinola1, Katri Puukka2, Terhi T Piltonen1, Johanna Puurunen1, Eszter Vanky3, Inger Sundström-Poromaa4, Elisabet Stener-Victorin5, Angelica Lindén Hirschberg6, Pernille Ravn7, Marianne Skovsager Andersen8, Dorte Glintborg8, Jan Roar Mellembakken9, Aimo Ruokonen2, Juha S Tapanainen10, Laure C Morin-Papunen11.   

Abstract

OBJECTIVE: To compare the metabolic profiles of normo- and hyperandrogenic women with polycystic ovary syndrome (PCOS) with those of control women at different ages during reproductive life.
DESIGN: Case-control study.
SETTING: Not applicable. PATIENT(S): In all, 1,550 women with normoandrogenic (n = 686) or hyperandrogenic (n = 842) PCOS and 447 control women were divided into three age groups: <30, 30-39, and >39 years). INTERVENTIONS(S): None. MAIN OUTCOME MEASURE(S): Body mass index (BMI), waist circumference, blood pressure, glucose, insulin, cholesterol, lipoproteins, triglycerides and high-sensitivity C-reactive protein. RESULT(S): Both normo- and hyperandrogenic women with PCOS were more obese, especially abdominally. They had increased serum levels of insulin (fasting and in oral glucose tolerance tests), triglycerides, low-density lipoprotein, and total cholesterol, higher blood pressure, and lower high-density lipoprotein levels independently from BMI compared with the control population as early as from young adulthood until menopause. The prevalence of metabolic syndrome was two- to fivefold higher in women with PCOS compared with control women, depending on age and phenotype, and the highest prevalence was observed in hyperandrogenic women with PCOS at late reproductive age. CONCLUSION(S): When evaluating metabolic risks in women with PCOS, androgenic status, especially abdominal obesity and age, should be taken into account, which would allow tailored management of the syndrome from early adulthood on.
Copyright © 2016 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  PCOS; hyperandrogenism; metabolism; obesity

Mesh:

Substances:

Year:  2017        PMID: 28089571     DOI: 10.1016/j.fertnstert.2016.12.017

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  24 in total

1.  Age at Onset of Metabolic Syndrome Among Women With and Without Polycystic Ovary Syndrome-Like Status.

Authors:  Qing Peng; Carrie A Karvonen-Gutierrez; John F Randolph; Bin Nan; Daniel McConnell; Siobán D Harlow
Journal:  J Clin Endocrinol Metab       Date:  2019-05-01       Impact factor: 5.958

Review 2.  Cardiometabolic Features of Polycystic Ovary Syndrome: Role of Androgens.

Authors:  Licy L Yanes Cardozo; Damian G Romero; Jane F Reckelhoff
Journal:  Physiology (Bethesda)       Date:  2017-09

3.  Effect of GLP-1 Receptor Agonists in the Cardiometabolic Complications in a Rat Model of Postmenopausal PCOS.

Authors:  Edgar D Torres Fernandez; Alexandra M Huffman; Maryam Syed; Damian G Romero; Licy L Yanes Cardozo
Journal:  Endocrinology       Date:  2019-12-01       Impact factor: 4.736

4.  Analysis of Endocrine and Metabolic Indexes in Non-Obese Patients with Polycystic Ovary Syndrome and Its Compare with Obese Patients.

Authors:  Wenjing Shi; Qi Zhao; Xue Zhao; Chuan Xing; Bing He
Journal:  Diabetes Metab Syndr Obes       Date:  2021-10-15       Impact factor: 3.168

5.  Incidental findings on coronary computed tomography in women with selected reproductive disorders.

Authors:  Kim van der Ham; Charissa van Zwol-Janssens; Birgitta K Velthuis; Maria P H Koster; Yvonne V Louwers; Dustin Goei; Maurits S H Blomjous; Arie Franx; Bart C J M Fauser; Eric Boersma; Joop S E Laven; Ricardo P J Budde
Journal:  Insights Imaging       Date:  2022-06-04

6.  Randomized controlled trial of astaxanthin impacts on antioxidant status and assisted reproductive technology outcomes in women with polycystic ovarian syndrome.

Authors:  Roghaye Gharaei; Ashraf Alyasin; Forough Mahdavinezhad; Esmaeil Samadian; Zhaleh Ashrafnezhad; Fardin Amidi
Journal:  J Assist Reprod Genet       Date:  2022-03-03       Impact factor: 3.357

7.  Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome.

Authors:  Dorte Glintborg; Katrine Hass Rubin; Mads Nybo; Bo Abrahamsen; Marianne Andersen
Journal:  Cardiovasc Diabetol       Date:  2018-03-08       Impact factor: 9.951

Review 8.  Curtailing PCOS.

Authors:  Selma Feldman Witchel; Helena J Teede; Alexia S Peña
Journal:  Pediatr Res       Date:  2019-10-18       Impact factor: 3.756

9.  Polycystic Ovary Syndrome (PCOS) Transition at Menopause.

Authors:  Duru Shah; Sabahat Rasool
Journal:  J Midlife Health       Date:  2021-04-17

10.  A Pilot Trial: Fish Oil and Metformin Effects on ApoB-Remnants and Triglycerides in Women With Polycystic Ovary Syndrome.

Authors:  Donna Vine; Ethan Proctor; Olivia Weaver; Mahua Ghosh; Katerina Maximova; Spencer Proctor
Journal:  J Endocr Soc       Date:  2021-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.